12:29 PM EDT, 06/28/2024 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Friday it secured $3.4 million in nondilutive funding to support its phase 2 trial of intranasal foralumab in nonactive secondary progressive multiple sclerosis and advance research in Alzheimer's disease.

"We continue to explore all avenues to pursue further nondilutive funding in the near term," acting Chief Executive Officer Gabriele Cerrone said.

Shares of the company rose 2.3% in recent Friday trading.

Price: 0.90, Change: +0.02, Percent Change: +2.27